MWNA
LUNG icon

Marshall Wace North America’s Pulmonx LUNG Stock Holding History

Marshall Wace North America’s Portfolio LUNG Stock Details LUNG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,062
Closed -$267K – 1598
2021
Q2 		$267K Buy
+6,062
New +$264K ﹤0.01% 1298

Other funds holding LUNG

Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

Marshall Wace North America's LUNG Position: Q3 2021 in Review

Marshall Wace North America sold out of Pulmonx (LUNG) in Q3 2021, closing a stake of 6,062 shares — an estimated $267K sold.

Marshall Wace North America first reported a position in LUNG in Q2 2021 and held it in 1 quarter. The position peaked at $267K in Q2 2021. 120 funds tracked by Wall St. Rank hold LUNG as of Q3 2021.

  • Marshall Wace North America reported no remaining Pulmonx position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 6,062 Pulmonx shares in Q3 2021, an estimated $267K.
  • Marshall Wace North America first reported a position in Pulmonx in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's Pulmonx position peaked at $267K in Q2 2021.
  • 120 funds tracked by Wall St. Rank held Pulmonx as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.